Lexilium

Bromazepam, the active ingredient in Lexilium, is a benzodiazepine presented as an oral dosage form for oral use. It is indicated for the short‑term relief of anxiety symptoms in adults. GNH USA supplies Lexilium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bromazepam acts on the central nervous system to alleviate anxiety‑related conditions. - Anxiety disorders: provides short‑term reduction of excessive worry and tension. - Generalized anxiety disorder: helps lower baseline anxiety levels during acute phases. - Pre‑operative anxiety: eases nervousness before surgical procedures.

Bromazepam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: light‑headed sensation, especially when standing quickly. - Impaired coordination: reduced motor control and balance. - Cognitive slowing: difficulty concentrating or remembering. - Gastrointestinal upset: nausea or mild stomach discomfort.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, particularly with high doses or other depressants. - Dependence or withdrawal: signs of physical or psychological dependence with prolonged use. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Mood changes: depression, irritability, or suicidal thoughts. - Paradoxical reactions: increased anxiety, agitation, or aggression.

Before prescribing Bromazepam, clinicians should consider several safety factors. - Assess renal and hepatic function: dose may need adjustment in impairment. - Review concomitant CNS depressants: avoid additive sedation. - Evaluate history of substance abuse: risk of dependence is higher. - Monitor elderly patients closely: increased sensitivity to sedation and falls. - Store at ambient temperature: keep below 25°C in the original container, protected from moisture.

Bromazepam can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Opioids: combined use may cause profound respiratory depression. - Barbiturates: additive CNS depression can be life‑threatening. - Alcohol: synergistic sedative effects increase accident risk.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may enhance serotonergic side effects. - Antihistamines: can increase drowsiness. - Anticonvulsants (e.g., carbamazepine): may reduce bromazepam plasma levels.